News

Astra Zeneca ends AZD2820 study
Enlarge image

BusinessSwedenUK

Astra Zeneca ends AZD2820 study

11.09.2012 - Swedish-British pharma Astra Zeneca has stopped the development of one obesity drug but promises to back partner Palatin with the other candidates.

US company Palatin Technologies, Inc. (Cranbury) experienced a setback for one of its developed drugs in June this year when its partner AstraZeneca PLC from Europe paused a Phase I clinical trial after a serious adverse event. Now, the Swedish-British pharma giant decided, after a thorough review, to end the development of this drug completely. However, Palatin also announced that AstraZeneca remains committed to the collaboration programme at large to discover, develop and commercialise compounds that target melanocortin-4 receptors for the treatment of obesity, diabetes and related metabolic syndrome.

The ditched clinical candidate called AZD2820 is a subcutaneously-administered peptide that partially agonises the melanocortin-4 receptor. Phase I clinical trials as a single-agent therapy for the treatment of obesity started in the first half of 2011 after AstraZeneca had selected the drug from the collaborative research programme with Palatin Technologies. The single centre study was expected to enrol 90 subjects with a body mass index between 30 and 35 in a randomised, single-blind, placebo-controlled, Phase I trial in healthy male volunteers. After 11 subjects had completed their dosing regimen, the trial was halted by the Safety Review Committee because it suspected that one subject may have had an allergic reaction following his first dose. The volunteer fully recovered but the review by AstraZeneca said that it cannot be excluded that the adverse reactiom was linked to AZD2820. The company however also stated, that it is unlikely that this event was related to melanocortin receptor activation as a mode of action.

http://www.european-biotechnology-news.com/news/news/2012-03/astra-zeneca-ends-azd2820-study.html

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.

R&DNetherlandsSpainAustria

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

    FLOP

      TOP

        FLOP

          TOP

            FLOP

              No liability assumed, Date: 06.07.2015